The article reports on the acquisition of Rinat Neuroscience Corp. by Pfizer Inc. in April 2006 in the U.S. David Pritchard, CEO of Rinat Neuroscience, explained that Pfizer was the highest bidders among nine drug companies that bid for the companies portfolio. Pfizer was interested on two monoclonal antibodies drugs coded as RN624 for pain treatment and RN1219 for Alzheimers disease.